David Apelian

2.6k total citations · 1 hit paper
36 papers, 1.9k citations indexed

About

David Apelian is a scholar working on Hepatology, Oncology and Immunology. According to data from OpenAlex, David Apelian has authored 36 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 13 papers in Oncology and 11 papers in Immunology. Recurrent topics in David Apelian's work include Hepatitis C virus research (14 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Research and Treatments (7 papers). David Apelian is often cited by papers focused on Hepatitis C virus research (14 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Research and Treatments (7 papers). David Apelian collaborates with scholars based in United States, New Zealand and Netherlands. David Apelian's co-authors include Robert G. Gish, Zachary Goodman, Ting‐Tsung Chang, Anna S. Lok, Jin Liang Zhu, Adrián Gadano, Richard B. Wilber, Deborah DeHertogh, Anne Cross and Jose D. Sollano and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

David Apelian

35 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

2006 1.1k citations Ting‐Tsung Chang, Robert G. Gish et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Apelian United States	16	1.3k	1.3k	343	315	253	36	1.9k
Barbara Testoni France	29	1.7k 1.3×	1.4k 1.1×	288 0.8×	279 0.9×	689 2.7×	77	2.3k
Hans Christian Spangenberg Germany	20	1.3k 1.0×	1.7k 1.3×	905 2.6×	266 0.8×	260 1.0×	42	2.5k
Hiroyuki Ohnuma Japan	17	547 0.4×	347 0.3×	134 0.4×	174 0.6×	252 1.0×	48	1.1k
Chu Chieh Hsia United States	19	784 0.6×	1.0k 0.8×	72 0.2×	328 1.0×	438 1.7×	27	1.6k
Noriyoshi Kuzushita Japan	21	563 0.4×	697 0.6×	521 1.5×	139 0.4×	200 0.8×	36	1.3k
B Ren China	13	1.9k 1.4×	1.4k 1.1×	263 0.8×	373 1.2×	570 2.3×	13	2.4k
Kiyoshi Mochizuki Japan	18	1.1k 0.9×	1.2k 0.9×	439 1.3×	195 0.6×	322 1.3×	44	1.9k
Patrick Soussan France	23	1.0k 0.8×	836 0.7×	191 0.6×	188 0.6×	381 1.5×	47	1.5k
Simona Schivazappa Italy	7	574 0.4×	550 0.4×	602 1.8×	278 0.9×	78 0.3×	9	1.1k
Anna Suk‐Fong Lok United States	17	1.1k 0.8×	1.1k 0.9×	106 0.3×	127 0.4×	119 0.5×	21	1.4k

Countries citing papers authored by David Apelian

Since Specialization

Citations

This map shows the geographic impact of David Apelian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Apelian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Apelian more than expected).

Fields of papers citing papers by David Apelian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Apelian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Apelian. The network helps show where David Apelian may publish in the future.

Co-authorship network of co-authors of David Apelian

This figure shows the co-authorship network connecting the top 25 collaborators of David Apelian. A scholar is included among the top collaborators of David Apelian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Apelian. David Apelian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cartwright, Douglas, Mark P. Lythgoe, Alexander K. Smith, et al.. (2025). 1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancer. Annals of Oncology. 36. S747–S747.

Muscarella, Peter, Tanios Bekaii‐Saab, Kristi McIntyre, et al.. (2021). A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. SHILAP Revista de lepidopterología. 7(1). 8–19. 17 indexed citations

Etzion, Ohad, Saeed Hamid, Yoav Lurie, et al.. (2019). PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. Journal of Hepatology. 70(1). e32–e32. 43 indexed citations

Gane, Edward, Christian Schwabe, Catherine Stedman, et al.. (2015). LP27 : ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase. Journal of Hepatology. 62. S277–S277. 3 indexed citations

Chaft, Jamie E., Anya M. Litvak, Maria E. Arcila, et al.. (2014). Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation. Clinical Lung Cancer. 15(6). 405–410. 64 indexed citations

Gaggar, Anuj, Claire Coeshott, David Apelian, et al.. (2014). Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study. Vaccine. 32(39). 4925–4931. 80 indexed citations

King, Thomas H., Zhimin Guo, Yingnian Lu, et al.. (2014). A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance. PLoS ONE. 9(7). e101904–e101904. 55 indexed citations

Ardiani, Andressa, Benedetto Farsaci, Connie J. Rogers, et al.. (2013). Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model. Clinical Cancer Research. 19(22). 6205–6218. 71 indexed citations

Bilušić, Marijo, Christopher R. Heery, Philip M. Arlen, et al.. (2013). Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunology Immunotherapy. 63(3). 225–234. 78 indexed citations

10.

Marshall, John L., Jimmy J. Hwang, Michael J. Pishvaian, et al.. (2012). A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS3638–TPS3638. 2 indexed citations

11.

Cereda, Vittore, Matteo Vergati, Ngar‐Yee Huen, et al.. (2011). Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine. 29(31). 4992–4999. 17 indexed citations

12.

Gameiro, Sofia R., et al.. (2011). Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunology Immunotherapy. 60(9). 1227–1242. 57 indexed citations

13.

D’Angelo, Sandra P., Lee M. Krug, Corey J. Crevar, et al.. (2011). Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations.. Journal of Clinical Oncology. 29(15_suppl). 7070–7070. 4 indexed citations

14.

Madan, Ravi A., Marijo Bilušić, James W. Hodge, et al.. (2011). A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA.. Journal of Clinical Oncology. 29(15_suppl). 2604–2604. 3 indexed citations

15.

Dai, Shaodong, Sarah Oakes, Richard C. Duke, et al.. (2010). Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine. 28(37). 6028–6035. 14 indexed citations

16.

McHutchison, John G., Gregory T. Everson, Ira M. Jacobson, et al.. (2010). 277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S116–S116. 3 indexed citations

17.

Guo, Zhimin, Yingnian Lu, Sarah Oakes, et al.. (2008). Trans-national patterns of pancreas cancer ras mutations and discovery of a new ras mutation with oncogenic synergy when found with ras codon 12 mutations. Clinical Cancer Research. 14. 1 indexed citations

18.

Duke, Richard C., et al.. (2007). Control of leukemia driven by T315I escape mutations in BCR-ABL with yeast-based Tarmogen immunotherapy. Molecular Cancer Therapeutics. 6. 2 indexed citations

19.

Chang, Ting‐Tsung, Robert G. Gish, Robert de Man, et al.. (2006). A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine. 354(10). 1001–1010. 1064 indexed citations breakdown →

20.

Haller, Aurelia A., Georg M. Lauer, Thomas H. King, et al.. (2006). Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 25(8). 1452–1463. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact